

Drug Policy

| | | |
|----------------|----------------------------|---|
| Policy: | Ponvory (ponesimod) | Annual Review Date: 05/16/2024 |
| | | Last Revised Date: 05/16/2024 |

OVERVIEW

Ponvory, a sphingosine 1-phosphate receptor modulator, is indicated for the treatment of patients with relapsing forms of **multiple sclerosis (MS)**, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease in adults.

POLICY STATEMENT

This policy involves the use of Ponvory. Prior authorization is recommended for pharmacy benefit coverage of Ponvory. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Ponvory as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Ponvory be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Ponvory is recommended in those who meet the following criteria:

- 1. Multiple Sclerosis; Initial Therapy**
Criteria. *Patient must meet the following criteria*
 - A) Patient has a relapsing form of multiple sclerosis; AND**
Note: Examples of relapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.
 - B) The patient is 18 years of age or older; AND**
 - C) The medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis.**

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

2. **Multiple Sclerosis; Patient is Currently Receiving Ponvory for ≥ 1 Year**

Criteria. *Patient must meet the following criteria*

A) Patient has a relapsing form of multiple sclerosis; AND

Note: Examples of relapsing forms of multiple sclerosis include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.

B) Patient meets one of the following (a or b):

a) Patient experienced a beneficial clinical response when assessed by at least one objective measure; OR

Note: Examples include stabilization or reduced worsening in disease activity as evaluated by magnetic resonance imaging (MRI) [absence or a decrease in gadolinium enhancing lesions, decrease in the number of new or enlarging T2 lesions]; stabilization or reduced worsening on the Expanded Disability State Scale (EDSS) score; achievement in criteria for No Evidence of Disease Activity-3 (NEDA-3) or NEDA-4; improvement on the fatigue symptom and impact questionnaire-relapsing multiple sclerosis (FSIQ-RMS) scale; reduction or absence of relapses; improvement or maintenance on the six-minute walk test or 12-Item MS Walking Scale; improvement on the Multiple Sclerosis Functional Composite (MSFC) score; and/or attenuation of brain volume loss.

b) Patient experienced stabilization, slowed progression, or improvement in at least one symptom such as motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling sensation; AND

C) Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis.

Initial Approval/ Extended Approval.

A) *Initial Approval:* 1 year

B) *Extended Approval:* 1 year

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Ponvory has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. Concurrent Use with Other Disease-Modifying Agents Used for Multiple Sclerosis.

These agents are not indicated for use in combination (See [Appendix](#) for examples). Additional data are required to determine if use of disease-modifying multiple sclerosis agents in combination is safe and provides added efficacy.

2. Non-Relapsing Forms of Multiple Sclerosis.

Drug Policy

Note: An example of a non-relapsing form of multiple sclerosis is primary progressive multiple sclerosis. The effectiveness of Ponvory in patients with primary progressive multiple sclerosis has not been established.

3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Ponvory™ tablets [prescribing information]. Titusville, NJ: Janssen; April 2021.
2. A Consensus Paper by the Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis. September 2019. Available at: http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color. Accessed on August 19, 2021.
3. McGinley MP, Goldschmidt C, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis. A review. *JAMA*. 2021;325(8):765-779.
4. No authors listed. Drugs for multiple sclerosis. *Med Lett Drugs Ther*. 2021;63(1620):42-48.
5. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014;83:278-286.
6. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018;17(2):162-173.

Drug Policy

APPENDIX

| Medication | Mode of Administration |
|---|-------------------------------|
| Aubagio® (teriflunomide tablets, generic) | Oral |
| Avonex® (interferon beta-1a intramuscular injection) | Injection (self-administered) |
| Bafiertam® (monomethyl fumarate delayed-release capsules) | Oral |
| Betaseron® (interferon beta-1b subcutaneous injection) | Injection (self-administered) |
| Briumvi® (ublituximab-xiij intravenous infusion) | Intravenous infusion |
| Copaxone® (glatiramer acetate subcutaneous injection, generic) | Injection (self-administered) |
| Extavia® (interferon beta-1b subcutaneous injection) | Injection (self-administered) |
| Gilenya® (fingolimod capsules, generic) | Oral |
| Glatopa® (glatiramer acetate subcutaneous injection) | Injection (self-administered) |
| Kesimpta® (ofatumumab subcutaneous injection) | Injection (self-administered) |
| Lemtrada® (alemtuzumab intravenous infusion) | Intravenous infusion |
| Mavenclad® (cladribine tablets) | Oral |
| Mayzent® (siponimod tablets) | Oral |
| Ocrevus® (ocrelizumab intravenous infusion) | Intravenous infusion |
| Plegridy® (peginterferon beta-1a subcutaneous or intramuscular injection) | Injection (self-administered) |
| Ponvory® (ponesimod tablets) | Oral |
| Rebif® (interferon beta-1a subcutaneous injection) | Injection (self-administered) |
| Tascenso ODT® (fingolimod orally disintegrating tablets) | Oral |
| Tecfidera® (dimethyl fumarate delayed-release capsules, generic) | Oral |
| Tyruko® (natalizumab-sztn intravenous infusion) | Intravenous infusion |
| Tysabri® (natalizumab intravenous infusion) | Intravenous infusion |
| Vumerity® (diroximel fumarate delayed-release capsules) | Oral |
| Zeposia® (ozanimod capsules) | Oral |

| Medication | Mode of Administration |
|---|-------------------------------|
| Aubagio® (teriflunomide tablets, generic) | Oral |
| Avonex® (interferon beta-1a intramuscular injection) | Injection (self-administered) |
| Bafiertam® (monomethyl fumarate delayed-release capsules) | Oral |
| Betaseron® (interferon beta-1b subcutaneous injection) | Injection (self-administered) |
| Briumvi® (ublituximab-xiij intravenous infusion) | Intravenous infusion |
| Copaxone® (glatiramer acetate subcutaneous injection, generic) | Injection (self-administered) |
| Extavia® (interferon beta-1b subcutaneous injection) | Injection (self-administered) |
| Gilenya® (fingolimod capsules, generic) | Oral |
| Glatopa® (glatiramer acetate subcutaneous injection) | Injection (self-administered) |
| Kesimpta® (ofatumumab subcutaneous injection) | Injection (self-administered) |
| Lemtrada® (alemtuzumab intravenous infusion) | Intravenous infusion |
| Mavenclad® (cladribine tablets) | Oral |
| Mayzent® (siponimod tablets) | Oral |
| Ocrevus® (ocrelizumab intravenous infusion) | Intravenous infusion |
| Plegridy® (peginterferon beta-1a subcutaneous or intramuscular injection) | Injection (self-administered) |
| Ponvory® (ponesimod tablets) | Oral |
| Rebif® (interferon beta-1a subcutaneous injection) | Injection (self-administered) |
| Tascenso ODT® (fingolimod orally disintegrating tablets) | Oral |

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

| | |
|--|----------------------|
| Tecfidera® (dimethyl fumarate delayed-release capsules, generic) | Oral |
| Tyruko® (natalizumab-sztn intravenous infusion) | Intravenous infusion |
| Tysabri® (natalizumab intravenous infusion) | Intravenous infusion |
| Vumerity® (diroximel fumarate delayed-release capsules) | Oral |
| Zeposia® (ozanimod capsules) | Oral |

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>